We studied the genetic expression of gp85 of avian leukaemia virus (ALV) subgroup A in a baculovirus/ insect cell system. 5'-terminal sequences of the gag gene were added to precede the ALV gp85 sequence and a stop codon was introduced at the boundary of gp85 and gp37. The resulting construct was then cloned into the baculovirus transfer vector pAcYM1, which contains the polyhedrin promoter ofA utographa californica nuclear polyhedrosis virus (AcNPV). Cells of the insect Spodopterafrugiperda (Sf9) were cotransfected with the resulting recombinant transfer vector pAc85 and infectious AcNPV/E2 DNA. After cotransfection, recombinant baculovirus that lacked the polyhedrin gene and expressed gp85 was selected from the supernatant and used to infect Sf9 cells. The expression of the gp85 gene peaked 3 days after infection, but expression products were not released into the culture medium even though the signal peptide had been cleaved. Owing to incomplete N-glycosylation in the insect cells the largest gp85 product had an Mr of only 65 000. In immunofluorescence tests and immunoblots the recombinant gp85 products reacted with polyclonal and monoclonal antibodies directed against ALV gp85 of subgroup A. Chickens inoculated with crude lysates of Sf9 cells infected with gp85-expressing recombinant baculovirus developed antibodies directed against ALV gp85. These antibodies were not capable of neutralizing ALV.
Introduction
Lymphoid leukosis in chickens is caused by the exogenous avian leukaemia virus (ALV) and is characterized by neoplastic lesions that proliferate in the lymphoid organs. These lesions first develop in follicles of the bursa of Fabricius, the primary organ in which avian B cells mature, and consist of B cells that express immunoglobulin M (Cooper et al., 1968; Pizer & Humphries, 1989) . Neoplastic cells from a single transformed follicle metastasize to visceral organs after a long incubation period of several months. The majority of ALV lymphomas contain proviral DNA that is integrated at a unique site near to the c-myc locus of the B cell genome (Neel et al., 1982; Baba & Humphries, 1985) .
The ALV genome consists of two identical ssRNA molecules (Coffin, 1982) containing three genes encoding the viral proteins gag, pol and env. The ALV envelope (env) gene encodes a single glycosylated precursor polypeptide that is processed during virus replication into two glycoproteins (gp) with Mr of 85000 (gp85) and 37000 (gp37) (Klemenz & Diggelmann, 1978) . These proteins are embedded in the viral envelope and remain linked to each other by disulphide bonds (Leamnson & Halpern, 1976) . Virus-neutralizing antibodies are 0000-9643 © 1990 SGM directed against gp85 (Ignjatovic et al., 1978; Wainberg et al., 1983) . Bova et al. (1986) suggested that the gp85 gene may contain regions that encode targets for neutralizing antibodies specific to ALV subgroups, as well as regions that may be important in interactions with the host cell receptor.
The baculovirus system was selected as a vector for gp85 expression because it is known to produce relatively large quantities of specific proteins (Luckow & Summers, 1988) . This system exploits the highly active polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcNPV) (Summers & Smith, 1987; Hooft van Iddekinge et al., 1983; Matsuura et al., 1987) .
After having established the synthesis of recombinant gp85 expression products in this system, we characterized the antigenic properties of the recombinant gp85 by immunofluorescence tests, immunoblots, and by inoculation of chickens.
Methods
Viruses, cells and viral glycoprotein. AcNPV/E2 (Smith & Summers, 1978) was obtained from Innogenetics and Spodopterafrugiperda (Sf9) cells were obtained from the American Tissue Culture Collection (no. CRL 1711). AcNPV/E2 and recombinant virus stocks were grown and assayed in confluent monolayers of Sf9 cells in TC-100 medium (Gibco/BRL) containing 10~ foetal bovine serum, 2.5 ~tg/ml fungizone and 50 ixg/ml gentamicin. Cells were cultured according to the methods of Summers & Smith (1987) . ALV subgroups A, B, C, D and E [Rousassociated viruses (RAV)] were obtained from the virus collection of the Central Veterinary Institute, Lelystad, The Netherlands. RAV-1 was purified from 1104-B1 lymphoblastoid cells (Hirara et aL, 1974) by use of routine sucrose gradient centrifugation, gp85 was isolated from purified RAV-1 via affinity chromatography on Sepharose/lentil lectin (Pharmacia).
Construction of the transfer vector pAc85. Plasmid DNA manipulations were performed essentially according to the methods described by Maniatis et al. (1982) .
Two DNA fragments containing env sequences were derived from clone pBr322/RAV-1 (a gift from Dr E. H. Humphries, University of Texas, Dallas, Tx., U.S.A.). One was a KpnI-XhoI (blunted) fragment (0.26 kb) containingpol and env DNA sequences; the other was a KpnI-SstI fragment (3 kb) containing pol, env and long terminal repeat sequences. These fragments were subcloned into two pUC 19 plasmids, designated pUCa and pUCb ( Fig. 1) .
As a result of alternative splicing, the env RNAs contain not only the env sequence, but also 18 nucleotides encoded by the gag gene (Bova et al., 1986) . The missing gag sequences had to be ligated to the 5' env sequences in order to express the complete gp85 precursor. Plasmid pUCa was digested with XbaI and HinfI and a 0.15 kb XbaI-Hinfl fragment was isolated. Plasmid pUCI9 was digested with XbaI and Asp718 and treated with calf intestine alkaline phosphatase (CIP); an XbaI-Asp718 fragment of 2.65 kb was then isolated. A synthetic DNA linker comprising 72 bases was ligated to the Xbal-HinfI (0.15 kb) and the XbaI-Asp718 (2.65 kb) fragments. This linker contained a flanking Asp718 site, a BamHI site, 18 bp of the gag sequence (including the ATG initiation codon), the env sequence and a flanking HinfI site. The resulting construct, pUCc, was analysed by restriction enzyme digestions and sequencing of the newly introduced sequences (Fig. 1) .
The gp85 protein originates from proteolytic cleavage of a precursor. To ensure that only gp85 would be formed, a translation stop codon was introduced at the gp85-gp37 boundary. Plasmid pUCb was digested with KpnI and MaelI and a 1.27 kb KpnI-MaelI fragment was isolated. Plasmid pUC19 was digested with BamHI and KpnI, treated with CIP and the 2.65 kb KpnI-BamHI fragment was isolated. A synthetic DNA linker comprising 14 bp was ligated to the KpnI-MaelI (1.27 kb) and the KpnI-BamHI (2-65 kb) fragments. The linker contained a flanking MaelI site, a translation stop codon and a flanking BamHI site. The resulting construct, pUCd, was analysed by sequencing of the 3' region of the env sequence and restriction enzyme digestions (Fig. 1) .
The complete gp85 precursor sequences in pUC19 DNA were then cloned. Plasmids pUCc and pUCd were digested with BamHI and XhoI and the 0.22 kb BamHI-XhoI fragment derived from pUCc and the 1.0 kb BamHI-XhoI fragment from pUCd were ligated to the CIPtreated BamHI site of pUC19. The resulting construct, pUC85, was analysed by restriction enzyme digestions ( Fig. 1) .
A baculovirus transfer vector was constructed by using pUC85 and the AcNPV transfer vector pAcYM1 (Matsuura et al., 1987) , donated by Professor D. H. L. Bishop, NERC Institute of Virology, Oxford, U.K. The 1.2 kb BamHI fragment derived from pUC85, which contained all of the gp85 precursor sequence, was cloned in the CIPtreated BamHI site of pAcYM 1. Restriction enzyme analysis was used to confirm that the coding sequence of the gp85 precursor was correctly oriented with the polyhedrin promoter ( Fig. l) . Finally, construct pAc85 was purified twice on a CsCI gradient and a Sephacryl S-500 (Pharmacia) column. DNA according to the method of Smith et al. (1983) who modified the transfection procedures of Graham & van der Eb (1973) . The supernatant containing extracelhlar baculoviruses was diluted in TC-100 medium to 20 p.f.u, per 100 ~tl and 96 microtitre wells, containing 2 x 10" Sf9 cells per well, were inoculated with 100 l-tl each. Supernatants from cell lysates that hybridized with a gp85-specific probe were analysed in a plaque assay using neutral red (Sigma), as described for the baculovirus system by Brown & Faulkner (1977) . The polyhedrin-negative plaques were inoculated onto a monolayer of Sf9 cells in a microtitre plate for dot-slot hybridization. Supernatants from strongly hybridizing cell lysates were analysed in plaque assays and, if the wild-type baculovirus phenotype was absent, the supernatants were used directly to make large stocks of the recombinant baculoviruses. Occasionally, an additional plaque assay/dot-slot cycle was performed.
Preparation of monoclonal antibodies directed against ALV gp85.
Monoclonal antibodies (MAb) directed against ALV gp85 were prepared as described for ALV p27 (De Boer & Osterhaus, 1985) . MAb CVI-ALV-61.6 stained an 85K protein in immunoblots using density gradient-purified ALV of subgroup A (RAV-1) (G. F. De Boer et al., unpublished results).
Immunoblotting. Electrophoresis was used to separate proteins from Sf9 cell lysates on 10~ SDS-polyacrylamide gels (Laemmli, 1970) . Proteins were electroblotted onto nitrocellulose membranes (Towbin et al., 1979) and the blots were incubated with either rabbit anti-MAV-2(0) gp85 serum diluted 1 : 125 (donated by Dr R. E. Smith, Fort Collins, Co., U.S.A.), an MAb directed against ALV gp85 (CVI-ALV-61.6) diluted 1:500, sera of chickens with virus-neutralizing antibodies directed against various ALV subgroups diluted 1:50, or serum collected from specific pathogen-free (SPF) chickens diluted 1:50. The bound antibody was detected with an appropriate second antibody conjugated to peroxidase, and 3,3', 5,5'-tetramethylbenzidine-dioctyl sodium sulphonate was used as substrate for the peroxidase.
Immunofluorescence assay. Sf9 cells, grown on coverslips, were infected with recombinant bacutovirus or AcNPV/E2. After incubation for 3 days at 28 °C, the cells were fixed with cold acetone for 10 min, washed in phosphate-buffered saline (PBS) and incubated with 5% normal goat serum for 30 min. The cells were incubated again for 1 h at room temperature with 25 ~tl of a 20-fold dilution of rabbit anti-MAV-2(0) gp85 serum and 5~ normal goat serum. After washing, the cells were stained for 1 h at room temperature with a 40-fold dilution of goat anti-rabbit IgG conjugated with fluorescein isothiocyanate and 5% normal goat serum. The preparations were then washed and examined for fluorescence.
Digestion with endoglycosidase H and endoglycosidase F/N-glycosidase
F. About 107 infected Sf9 ceils were resuspended in 200 ~tl PBS. The Sf9 cells were pelleted, resuspended in 1 ml PBS containing 1% Nonidet P-40, sonicated and incubated at room temperature for 1 h. The mixture was divided into two 500 ~tl fractions, centrifuged and the pellets containing gp85 were resuspended in 40 kt150 raM-citric acid/50 mM-Na2HPO4, 1 ~ SDS and 10~ 2-mercaptoethanol pH 6.0 (mix A) or pH 7.0 (mix B). Both mixtures were boiled for 4 rain, cooled at room temperature and centrifuged. Supernatant (4 ~tl) was added to 36 ~tl mix A or mix B containing 10 mM-EDTA, 1 mM-PMSF and 0-5% Nonidet P-40, instead of 1 ~ SDS and 2-mercaptoethanol. Endoglycosidase H (10 mU) (Boehringer Mannheim) was added to mix A and 50 mU endoglycosidase F/N-glycosidase F (Boehringer Mannheim) was added to mix B, after which both mixes were incubated for 18 h at 37 °C. In addition, mix A and mix B were incubated without the addition of glycosidases under the same conditions and were used as negative controls. The samples were analysed by immunoblotting.
Immunization procedure. Adult SPF chickens were inoculated intraperitoneally and subcutaneously with lysates of 4 x 107 Sf9 cells expressing recombinant gp85 in Freund's complete adjuvant. The chickens received booster injections of 4 x 107 Sf9 cells expressing recombinant gp85 in incomplete Freund's adjuvant 4 weeks later. Blood samples were collected at 2 week intervals after the immunizations and tested by an indirect ELISA (IDAS-ELISA) using microtitre plates coated with affinity chromatography-purified ALV gp85, according to the procedures described by De Boer & Osterhaus (1985) , and by immunoblots of purified ALV subgroup A (RAV-1) virus. The plaque reduction assay was performed as described by Spencer (1987) .
Results

Construction of recombinant baculovirus
The strategy used for the construction of the transfer vector encoding the A L V gp85 precursor is outlined in the Methods section and in Fig. 1 . P l a s m i d pAc85 lacks the complete polyhedrin coding sequence, contains all the upstream and leader sequences of the polyhedrin gene, including nucleotide A of the start codon o f the polyhedrin gene, and 3' non-coding sequences including (Kozak, 1986 ) was inserted.
To transfer the gp85 precursor coding sequences into the A c N P V / E 2 baculovirus genome, we cotransfected Sf9 cells with pAc85 and wild-type A c N P V / E 2 D N A . R e c o m b i n a n t virus was initially identified by analysing lysates of infected cells that had been h y b r i d i z e d to a gp85-specific D N A p r o b e ; thereafter, virus was visually identified by isolating plaques that were negative for viral polyhedra.
Expression and characterization of recombinant gp85 in S f9 cells
Six r e c o m b i n a n t baculovirus constructs were initially identified; all synthesized a p p r o x i m a t e l y equal amounts of gp85 in Af9 cells (data not shown). Only one clone, pAc85/6, was used for the subsequent studies.
In immunofluorescence assays, Sf9 cells infected with r e c o m b i n a n t baculovirus were specifically stained by a r a b b i t serum directed against MAV-2(0) gp85. Cells infected with wild-type virus were not stained (Fig. 2) .
N o gp85 products were detected a t the time of infection or on day 1 post-infection (p.i.) (Fig. 3) . The intracellular accumulation of gp85 products was estimated as 1 to 2 ~tg per 106 cells and p e a k e d 3 days p.i. Several distinct gp85 products with Mr values ranging from 45 000 to 65 000 were detected. N o gp85 products were detected in the supernatant of infected Sf9 cells, indicating that gp85 is secreted into the m e d i u m in very small quantities, if at all (data not shown). Lysates of Sf9 cells infected with wild-type baculovirus did not produce gp85-specific bands in an i m m u n o b l o t assay (Fig. 4) . When tunicamycin, which blocks N-glycosylation of proteins, was added to the medium of Sf9 cells infected with recombinant baculovirus, 45K and 38K proteins were stained (Fig. 4) . These proteins had the Mr values expected for unmodified protein with and without signal peptide. The minor product, of 39K, is most likely produced by a proteolytic cleavage at a cryptic site.
Affinity-purified ALV gp85 had a heterogenous Mr of around 85000 (Fig. 5b) . When gp85 is expressed in the baculovirus system the largest glycosylated gp85 product had an M r of only 65000 (Fig. 5a ). To analyse whether this difference in Mr is caused by differences in the Nglycosylation of the two cell types, we digested gp85 from both cell types with endoglycosidase F/N-glycosidase F or endoglycosidase H. Endoglycosidase F/Noglycosidase F digestion of recombinant gp85 resulted in a 38K protein and a 45K protein (Fig. 5 a) , as was also observed for affinity-purified ALV gp85 (Fig. 5b) ; there was relatively more 45K product present in the recombinant gp85 sample. The bulk of the oligosaccharides of ALV gp85 was resistant to endoglycosidase H (Fig. 5b) , whereas the oligosaccharides of recombinant gp85 were predominantly sensitive (Fig. 5a ). We conclude that maturation to complex-type oligosaccharides did not occur, and therefore the recombinant gp85 appeared to be incompletely glycosylated. 6) at an m.o.i, of 5 p.f.u, per cell and incubated for 4 h at 28°C. Subsequently, the culture media were replaced by media containing 0 (lanes 3 and 6), 1 (lanes 2 and 5) or 10 ~tg (lanes 1 and 4) oftunicamycin per ml. Infected Sf9 cells were incubated for 3 days at 28 °C. Cell lysates were analysed by Western blot assays, gp85 was stained with MAb CVI-ALV-61.6.
Antigenicity of recombinant gp85
Sera collected from chickens inoculated with various subgroups of ALV were tested for their ability to react with the recombinant gp85 in immunoblots of crude extracts of Sf9 cells infected with recombinant baculovirus (Table 1) . Sera from chickens containing virusneutralizing antibodies against ALV subgroup A and a mouse MAb directed against ALV gp85 (CVI-ALV-61.6) bound with the recombinant gp85 products. Sera from chickens with neutralizing antibodies against other ALV subgroups and normal chicken serum showed no binding with recombinant gp85 products.
Immune response in chickens
Sera of chickens immunized with crude extracts of Sf9 cells expressing recombinant gp85 and sera of chickens infected with RAV-1 were tested in immunoblots to determine their binding to ALV proteins (Fig. 6 ). Sera of chickens inoculated with recombinant gp85 reacted with ALV gp85, whereas sera from chickens infected with RAV-1 reacted with ALV gag proteins and gp85. Sera . Western blots of purified ALV-RAV-1 stained with sera of chickens immunized with recombinant gp85. RAV-1 proteins were separated by electrophoresis on 10~ polyacrylamide-SDS gels and transferred onto nitrocellulose filters. Blots were stained with serum collected from three different chickens before the first immunization with recombinant gp85 (lanes 1 to 3) , or 2 weeks after the booster immunization of the corresponding chickens (lanes 4 to 6). Blots stained with the serum of RAV-l-infected chickens are shown in lanes 7 and 8. 
Discussion
This report describes the expression of the ALV gp85 env gene by recombinant baculoviruses. Since the neutralizing epitopes are localized in the gp85 gene, we inserted only gp85 and not the entire env precursor into the baculovirus vector. Bova et al. (1986) determined the 340 amino acid sequence that encodes gp85 of the Schmidt-Ruppin strain of ALV subgroup A. The precursor of gp85 contains a signal peptide of 62 amino acids which is rapidly removed during biosynthesis (Hunter et al., 1983) . With tunicamycin treatment we obtained unglycosylated products with Mr of 45000 and 38000. These data indicate that the gp85 polypeptide was synthesized correctly and that the signal peptide of gp85 was cleaved off in the baculovirus expression system.
Gp85 of RSV (RAV-1) contains both major classes of asparagine-linked oligosaccharide chains: the complex acidic structures that contain sialic acid, galactose, N-acetylglucosamine, mannose and fucose and the mannose-rich neutral structures that also contain Nacetylglucosamine (Krantz et al., 1976; Hunt et al., 1979) . Indeed, in ALV-infected chicken embryo fibroblasts as well as in COS-1 [simian virus 40 (SV40)transformed African green monkey kidney] cells transiently transfected with an SV40 vector expressing recombinant gp85 (data not shown), the gp85 product of Mr 85000 was synthesized, in accordance with our expectations. In insect cells, however, the largest gp85 product had an Mr of only 65 000.
Endoglycosidase F/N-glycosidase F treatment of both ALV and recombinant gp85 resulted in 38K and 45K unglycosylated proteins. The fact that relatively more 45K protein was produced in the baculovirus/insect cell system, as compared with a normal ALV infection, suggests that the signal peptide of gp85 was less efficiently cleaved in insect ceils. The bulk of the oligosaccharides of recombinant gp85 were more sensitive to endoglycosidase H treatment than native ALV gp85. Endoglycosidase H digestion of recombinant gp85 results in somewhat larger products than those obtained after endoglycosidase F/N-glycosidase treatment. This difference might be due to the fact that endoglycosidase H leaves N-acetylglucosamine residues attached to the polypeptides, whereas endoglycosidase F/N-glycosidase F digestion removes the entire oligosaccharide. From these data we concluded that most, if not all, of the oligosaccharides of recombinant gp85 are not of the complex type.
The gp85 products present in Sf9 lysates did not dissolve in 1% Nonidet P-40 or 1% deoxycholate (data not shown). The insolubility may be due to aggregation of abnormally large amounts of protein with unmatured oligosaccharides, which accumulate in the endoplasmic reticulum. In our view, it may explain the incomplete glycosylation of recombinant gp85 in Sf9 ceils. From our data, however, it remains unclear whether the aberrant glycosylation of gp85 in Sf9 cells is due to the properties of gp85 itself, or to lack of appropriate enzymes.
Our results agree with the aberrant glycosylation in the baculovirus/insect cell system described for avian influenza virus haemagglutinin (Kuroda et al., 1990; Possee, 1986) , human epidermal growth factor (Greenfield et al., 1988) , Sindbis virus E1 protein and the gD protein of herpes simplex virus type 1 (HSV-1) (Krishna et al., 1989) . Although N-linked glycosylation does occur in baculovirus-infected insect cells (reviewed by Luckow & Summers, 1988) , complex residues are not added (Kuro~ta et al., 1990) . However, it remains questionable whether insect cells produce complex-type saccharides at all because Hsieh & Robbins (1984) demonstated that such oligosaccharides were not detected in mosquito ceils.
Based on the specific binding of recombinant gp85 with chicken sera directed against ALV subgroup A, we demonstrated that the recombinant gp85 contains subgroup-specific epitopes. Recombinant gp85 obtained from insect cells elicited an antibody response in chickens but no neutralizing activity was observed. However, the failure of these antibodies to neutralize RSV in a plaque reduction assay may not necessarily be due to the abnormal glycosylation of gp85. Other baculovirus-expressed glycoproteins, such as influenza virus haemagglutinin (Kuroda et al., 1986 ) and gD of HSV-1 (Krishna et al., 1989) , induced neutralizing antibodies in immunized animals despite their aberrant glycosylation.
Conformational epitopes are probably essential for the induction of neutralizing antibodies but, on the other hand, failure to induce neutralizing antibodies is not always a prerequisite for protective immunity, as Hunt et al. (1988) showed for chickens vaccinated with influenza virus haemagglutinin. Therefore, in our situation, the absence of neutalizing antibodies does not imply that the recombinant gp85 product will not provide protection.
Two recent reports described transport-limiting steps for foreign glycoproteins produced in insect cells by use of a baculovirus. These glycoproteins were inefficiently secreted into the medium, possibly due to inefficient transport of these proteins in insect cells (Jarvis & Summers, 1989; ; we failed to observe any secretion of gp85 into the medium. Another limiting factor on efficient transport through the endoplasmic reticulum might have been the omission of gp37 from our construct in this study. The gp37 polypeptides are essential for the formation of trimers during the biosynthesis of the RSV envelope (Einfeld & Hunter, 1988) and are thereby essential for transport and perhaps other biological functions. For example, conformational epitopes present in trimers of gp85 and gp37 might be essential for the induction of neutralizing antibodies and protection. Therefore, in further experimental trials in chickens gp37 will be included.
In conclusion, our experiments prove that our baculovirus vector is fully capable of expressing the ALV gp85 gene. Although the baculovirus/insect cell system yielded incomplete glycosylation, the recombinant gp85 showed antigenic properties specific for native gp85. In the chicken, recombinant gp85 induced specific antibodies against ALV gp85, but no neutralizing antibodies. The immunizing potential of the recombinant gp85 will be tested in further experiments.
